Telix Pharmaceuticals has completed enrollment in its pivotal Phase 3 BiPASS trial for prostate cancer imaging and aligned with the FDA on a pathway that could expand U.S. patient access and reimbursement for its 68Ga-PSMA-PET agents.
- Phase 3 BiPASS study enrolls 350 patients in US and Australia
- FDA alignment on New Drug Application pathway for Illuccix and Gozellix
- BiPASS evaluates combined 68Ga-PSMA-PET and MRI to improve pre-biopsy diagnosis
- Potential to reduce unnecessary prostate biopsies by nearly 50%
- Could broaden access to advanced imaging beyond current staging use
BiPASS Enrollment Marks Pivotal Clinical Milestone
Telix Pharmaceuticals (ASX:TLX, NASDAQ: TLX) has completed patient enrollment in its Phase 3 BiPASS trial, a key step testing its prostate cancer imaging agents Illuccix and Gozellix in a pre-biopsy setting. The study recruited 350 patients across the U.S. and Australia, aiming to validate whether combining 68Ga-PSMA-PET with MRI can enhance diagnostic accuracy and reduce the number of unnecessary biopsies.
Globally, prostate biopsies exceed three million annually, with up to 75% returning negative results, highlighting a significant clinical inefficiency. Biopsy procedures can be stressful, painful, and carry risks without benefiting many patients. Telix’s BiPASS study seeks to address these challenges by potentially sparing many men from invasive biopsies through more precise imaging.
FDA Alignment Opens Door for Broader U.S. Access
Alongside enrollment completion, Telix has secured alignment with the U.S. Food and Drug Administration on a New Drug Application (NDA) pathway for the BiPASS data. If approved, this would support reimbursement for Illuccix and Gozellix, expanding patient access to 68Ga-PSMA-PET imaging well beyond its current use in initial staging and disease recurrence assessment.
This regulatory progress signals a strategic opportunity for Telix to position its imaging agents as a frontline diagnostic tool, potentially transforming prostate cancer management by enabling earlier, non-invasive detection of clinically significant disease.
Building on Landmark PRIMARY Studies
BiPASS builds on the foundation laid by the PRIMARY and PRIMARY2 studies, which demonstrated that combining 68Ga-PSMA-PET with MRI can safely reduce biopsies by nearly half without missing significant cancers. If BiPASS confirms these findings, it could shift the diagnostic standard of care, streamlining patient pathways and accelerating treatment decisions.
Experts involved in the trial emphasise the potential patient benefits, including less procedural anxiety and risk, alongside more tailored treatment strategies. Professor Louise Emmett of St Vincent’s Hospital noted that BiPASS could fundamentally change diagnostic protocols, particularly for patients with ambiguous MRI results.
Telix’s Position in the Theranostics Landscape
Telix’s commercial prostate imaging portfolio, anchored by Illuccix and Gozellix, is already available in 22 countries including the U.S. The company’s broader theranostics pipeline includes several late-stage therapeutic candidates targeting prostate, kidney, and brain cancers.
Completion of BiPASS enrollment and FDA alignment come amid a period of strong commercial momentum for Telix, following recent financial gains and strategic partnerships. This clinical and regulatory progress could further enhance Telix’s market positioning in precision oncology diagnostics.
Bottom Line?
Telix’s BiPASS milestone and FDA alignment set the stage for a potential paradigm shift in prostate cancer diagnosis, but the market will await trial outcomes and regulatory decisions before recalibrating expectations.
Questions in the middle?
- Will BiPASS data confirm the biopsy reduction seen in earlier PRIMARY studies?
- How quickly will Telix submit the NDA and what feedback will the FDA provide?
- Could expanded reimbursement for 68Ga-PSMA-PET imaging reshape prostate cancer diagnostic pathways?